Literature DB >> 17540852

Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.

Animesh Pardanani1, Terra L Lasho, Christy Finke, Ruben A Mesa, William J Hogan, Rhett P Ketterling, Dwight Gary Gilliland, Ayalew Tefferi.   

Abstract

JAK2V617F and MPLW515L/K are myeloproliferative disorder (MPD)-associated mutations. We genotyped 552 individual hematopoietic colonies obtained by CD34+ cell culture from 16 affected patients (13 JAK2V617F and 3 MPLW515L/K) to determine (a) the proportion of colonies harboring a particular mutation in the presence or absence of cytokines, (b) the lineage distribution of endogenous colonies for each mutation, and (c) the differences (if any) in the pattern of mutation among the various MPDs, as established by genotyping of individual colonies. Genotyping analysis revealed cohabitation of mutation-negative and mutation-positive endogenous colonies in polycythemia vera as well as other MPDs. Culture of progenitor cells harboring MPLW515L/K yielded virtually no endogenous erythroid colonies in contrast to JAK2V617F-harboring progenitor cells. The mutation pattern (i.e., relative distribution of homozygous, heterozygous, or wild-type colonies) was not a distinguishing feature among the MPDs, and MPLW515 mutations were detected in B and/or T lymphocytes in all three patients tested. These observations suggest that clonal myelopoiesis antedates acquisition of JAK2V617F or MPLW515L/K mutations and that the latter is acquired in a lympho-myeloid progenitor cell.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17540852     DOI: 10.1634/stemcells.2007-0175

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  19 in total

1.  JAK2-V617F-mutated myeloproliferative neoplasms reveal different allele burden within hematopoietic cell lineages: a microdissection study of bone marrow trephine biopsies.

Authors:  Andreas Kreft; Thomas Kindler; Erik Springer; Charles James Kirkpatrick
Journal:  Virchows Arch       Date:  2011-10-18       Impact factor: 4.064

2.  Pediatric essential thrombocythemia (ET) from the Czech Republic.

Authors:  Scott J Samuelson; Josef T Prchal
Journal:  Leuk Res       Date:  2007-09-07       Impact factor: 3.156

3.  Off-pump coronary artery surgery in a patient with essential thrombocythaemia: two life-threatening complications in the same patient.

Authors:  Kaan Kaya; Raif Cavolli; Alpaslan Telli; Refik Tasoz
Journal:  BMJ Case Rep       Date:  2009-08-25

Review 4.  Myeloproliferative neoplasms: from origins to outcomes.

Authors:  Jyoti Nangalia; Anthony R Green
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 5.  An immune dysregulation in MPN.

Authors:  Giovanni Barosi
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

6.  Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.

Authors:  Edit Porpaczy; Sabrina Tripolt; Andrea Hoelbl-Kovacic; Bettina Gisslinger; Zsuzsanna Bago-Horvath; Emilio Casanova-Hevia; Emmanuelle Clappier; Thomas Decker; Sabine Fajmann; Daniela A Fux; Georg Greiner; Sinan Gueltekin; Gerwin Heller; Harald Herkner; Gregor Hoermann; Jean-Jacques Kiladjian; Thomas Kolbe; Christoph Kornauth; Maria-Theresa Krauth; Robert Kralovics; Leonhard Muellauer; Mathias Mueller; Michaela Prchal-Murphy; Eva Maria Putz; Emmanuel Raffoux; Ana-Iris Schiefer; Klaus Schmetterer; Christine Schneckenleithner; Ingrid Simonitsch-Klupp; Cathrin Skrabs; Wolfgang R Sperr; Philipp Bernhard Staber; Birgit Strobl; Peter Valent; Ulrich Jaeger; Heinz Gisslinger; Veronika Sexl
Journal:  Blood       Date:  2018-06-14       Impact factor: 22.113

7.  Concomitant JAK2 V617F-positive polycythemia vera and B-cell chronic lymphocytic leukemia in three patients originating from two separate hematopoietic stem cells.

Authors:  Sabina Swierczek; Jitka Nausova; Jaroslav Jelinek; Enli Liu; Paul Roda; Jana Kucerova; Marie Jarosova; Helena Urbankova; Karel Indrak; Josef T Prchal; Vladimir Divoky
Journal:  Am J Hematol       Date:  2012-12-24       Impact factor: 10.047

8.  TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.

Authors:  A Tefferi; A Pardanani; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; N Gangat; C M Finke; S Schwager; A Mullally; C-Y Li; C A Hanson; R Mesa; O Bernard; F Delhommeau; W Vainchenker; D G Gilliland; R L Levine
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

Review 9.  Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.

Authors:  J-J Kiladjian; S Giraudier; B Cassinat
Journal:  Leukemia       Date:  2015-11-25       Impact factor: 11.528

Review 10.  Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.

Authors:  Ayalew Tefferi; Radek Skoda; James W Vardiman
Journal:  Nat Rev Clin Oncol       Date:  2009-10-06       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.